cdk4 6 inhibitor (MedChemExpress)
MedChemExpress is a verified supplier 
MedChemExpress manufactures this product 
96
Structured Review
MedChemExpress
cdk4 6 inhibitor
Cdk4 6 Inhibitor, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 96/100, based on 142 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cdk4+6+inhibitor/Abemaciclib/pm41986499-414-16-19
Average 96 stars, based on 142 article reviews
Cdk4 6 Inhibitor, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 96/100, based on 142 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cdk4+6+inhibitor/Abemaciclib/pm41986499-414-16-19
Average 96 stars, based on 142 article reviews
cdk4 6 inhibitor - by Bioz Stars,
2026-09
96/100 stars
Images
Related Articles
Cell Culture:Article Title: A NIR-Ⅱ Fluorescent Probe for Real-Time Visualization and Early Assessment of Responses to CDK4/6 Inhibitors in Breast Cancer. Article Snippet: This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record.. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article.. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. Article Title: The CDK4/6-UCHL5-BRD4 axis confers resistance to BET inhibitors in MLL-rearranged leukemia cells by suppressing BRD4 protein degradation. Article Snippet: Among acute leukemias, mixed-lineage leukemia-rearranged (MLL-r) leukemia is associated with poor prognosis.. Bromodomain and extra-terminal inhibitors (BETi) are promising agents for treatment of hematological malignancies; however, the mechanisms underlying sensitivity to BETi and biomarkers to predict sensitivity are yet to be clarified.. Here, we established OTX015-resistant MLL-r cell lines (OTX015R cells) and used them to explore therapeutic targets in BETi-resistant MLL-r leukemia. Standard Deviation:Article Title: A NIR-Ⅱ Fluorescent Probe for Real-Time Visualization and Early Assessment of Responses to CDK4/6 Inhibitors in Breast Cancer. Article Snippet: This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record.. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article.. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. Article Title: The CDK4/6-UCHL5-BRD4 axis confers resistance to BET inhibitors in MLL-rearranged leukemia cells by suppressing BRD4 protein degradation. Article Snippet: Among acute leukemias, mixed-lineage leukemia-rearranged (MLL-r) leukemia is associated with poor prognosis.. Bromodomain and extra-terminal inhibitors (BETi) are promising agents for treatment of hematological malignancies; however, the mechanisms underlying sensitivity to BETi and biomarkers to predict sensitivity are yet to be clarified.. Here, we established OTX015-resistant MLL-r cell lines (OTX015R cells) and used them to explore therapeutic targets in BETi-resistant MLL-r leukemia. Activity Assay:Article Title: A NIR-Ⅱ Fluorescent Probe for Real-Time Visualization and Early Assessment of Responses to CDK4/6 Inhibitors in Breast Cancer. Article Snippet: This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record.. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article.. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. Article Title: The CDK4/6-UCHL5-BRD4 axis confers resistance to BET inhibitors in MLL-rearranged leukemia cells by suppressing BRD4 protein degradation. Article Snippet: Among acute leukemias, mixed-lineage leukemia-rearranged (MLL-r) leukemia is associated with poor prognosis.. Bromodomain and extra-terminal inhibitors (BETi) are promising agents for treatment of hematological malignancies; however, the mechanisms underlying sensitivity to BETi and biomarkers to predict sensitivity are yet to be clarified.. Here, we established OTX015-resistant MLL-r cell lines (OTX015R cells) and used them to explore therapeutic targets in BETi-resistant MLL-r leukemia. Expressing:Article Title: A NIR-Ⅱ Fluorescent Probe for Real-Time Visualization and Early Assessment of Responses to CDK4/6 Inhibitors in Breast Cancer. Article Snippet: This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record.. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article.. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. Article Title: The CDK4/6-UCHL5-BRD4 axis confers resistance to BET inhibitors in MLL-rearranged leukemia cells by suppressing BRD4 protein degradation. Article Snippet: Among acute leukemias, mixed-lineage leukemia-rearranged (MLL-r) leukemia is associated with poor prognosis.. Bromodomain and extra-terminal inhibitors (BETi) are promising agents for treatment of hematological malignancies; however, the mechanisms underlying sensitivity to BETi and biomarkers to predict sensitivity are yet to be clarified.. Here, we established OTX015-resistant MLL-r cell lines (OTX015R cells) and used them to explore therapeutic targets in BETi-resistant MLL-r leukemia. Inhibition:Article Title: A NIR-Ⅱ Fluorescent Probe for Real-Time Visualization and Early Assessment of Responses to CDK4/6 Inhibitors in Breast Cancer. Article Snippet: This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record.. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article.. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. Article Title: The CDK4/6-UCHL5-BRD4 axis confers resistance to BET inhibitors in MLL-rearranged leukemia cells by suppressing BRD4 protein degradation. Article Snippet: Among acute leukemias, mixed-lineage leukemia-rearranged (MLL-r) leukemia is associated with poor prognosis.. Bromodomain and extra-terminal inhibitors (BETi) are promising agents for treatment of hematological malignancies; however, the mechanisms underlying sensitivity to BETi and biomarkers to predict sensitivity are yet to be clarified.. Here, we established OTX015-resistant MLL-r cell lines (OTX015R cells) and used them to explore therapeutic targets in BETi-resistant MLL-r leukemia. Activation Assay:Article Title: A NIR-Ⅱ Fluorescent Probe for Real-Time Visualization and Early Assessment of Responses to CDK4/6 Inhibitors in Breast Cancer. Article Snippet: This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record.. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article.. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. Article Title: The CDK4/6-UCHL5-BRD4 axis confers resistance to BET inhibitors in MLL-rearranged leukemia cells by suppressing BRD4 protein degradation. Article Snippet: Among acute leukemias, mixed-lineage leukemia-rearranged (MLL-r) leukemia is associated with poor prognosis.. Bromodomain and extra-terminal inhibitors (BETi) are promising agents for treatment of hematological malignancies; however, the mechanisms underlying sensitivity to BETi and biomarkers to predict sensitivity are yet to be clarified.. Here, we established OTX015-resistant MLL-r cell lines (OTX015R cells) and used them to explore therapeutic targets in BETi-resistant MLL-r leukemia. Histone Deacetylase Assay:Article Title: A NIR-Ⅱ Fluorescent Probe for Real-Time Visualization and Early Assessment of Responses to CDK4/6 Inhibitors in Breast Cancer. Article Snippet: This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record.. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article.. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. Article Title: The CDK4/6-UCHL5-BRD4 axis confers resistance to BET inhibitors in MLL-rearranged leukemia cells by suppressing BRD4 protein degradation. Article Snippet: Among acute leukemias, mixed-lineage leukemia-rearranged (MLL-r) leukemia is associated with poor prognosis.. Bromodomain and extra-terminal inhibitors (BETi) are promising agents for treatment of hematological malignancies; however, the mechanisms underlying sensitivity to BETi and biomarkers to predict sensitivity are yet to be clarified.. Here, we established OTX015-resistant MLL-r cell lines (OTX015R cells) and used them to explore therapeutic targets in BETi-resistant MLL-r leukemia. Blocking Assay:Article Title: A NIR-Ⅱ Fluorescent Probe for Real-Time Visualization and Early Assessment of Responses to CDK4/6 Inhibitors in Breast Cancer. Article Snippet: This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record.. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article.. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. Article Title: The CDK4/6-UCHL5-BRD4 axis confers resistance to BET inhibitors in MLL-rearranged leukemia cells by suppressing BRD4 protein degradation. Article Snippet: Among acute leukemias, mixed-lineage leukemia-rearranged (MLL-r) leukemia is associated with poor prognosis.. Bromodomain and extra-terminal inhibitors (BETi) are promising agents for treatment of hematological malignancies; however, the mechanisms underlying sensitivity to BETi and biomarkers to predict sensitivity are yet to be clarified.. Here, we established OTX015-resistant MLL-r cell lines (OTX015R cells) and used them to explore therapeutic targets in BETi-resistant MLL-r leukemia. Binding Assay:Article Title: A NIR-Ⅱ Fluorescent Probe for Real-Time Visualization and Early Assessment of Responses to CDK4/6 Inhibitors in Breast Cancer. Article Snippet: This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record.. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article.. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. Article Title: The CDK4/6-UCHL5-BRD4 axis confers resistance to BET inhibitors in MLL-rearranged leukemia cells by suppressing BRD4 protein degradation. Article Snippet: Among acute leukemias, mixed-lineage leukemia-rearranged (MLL-r) leukemia is associated with poor prognosis.. Bromodomain and extra-terminal inhibitors (BETi) are promising agents for treatment of hematological malignancies; however, the mechanisms underlying sensitivity to BETi and biomarkers to predict sensitivity are yet to be clarified.. Here, we established OTX015-resistant MLL-r cell lines (OTX015R cells) and used them to explore therapeutic targets in BETi-resistant MLL-r leukemia. Modification:Article Title: A NIR-Ⅱ Fluorescent Probe for Real-Time Visualization and Early Assessment of Responses to CDK4/6 Inhibitors in Breast Cancer. Article Snippet: This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record.. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article.. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. Article Title: The CDK4/6-UCHL5-BRD4 axis confers resistance to BET inhibitors in MLL-rearranged leukemia cells by suppressing BRD4 protein degradation. Article Snippet: Among acute leukemias, mixed-lineage leukemia-rearranged (MLL-r) leukemia is associated with poor prognosis.. Bromodomain and extra-terminal inhibitors (BETi) are promising agents for treatment of hematological malignancies; however, the mechanisms underlying sensitivity to BETi and biomarkers to predict sensitivity are yet to be clarified.. Here, we established OTX015-resistant MLL-r cell lines (OTX015R cells) and used them to explore therapeutic targets in BETi-resistant MLL-r leukemia. In Vitro:Article Title: A NIR-Ⅱ Fluorescent Probe for Real-Time Visualization and Early Assessment of Responses to CDK4/6 Inhibitors in Breast Cancer. Article Snippet: This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record.. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article.. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. Article Title: The CDK4/6-UCHL5-BRD4 axis confers resistance to BET inhibitors in MLL-rearranged leukemia cells by suppressing BRD4 protein degradation. Article Snippet: Among acute leukemias, mixed-lineage leukemia-rearranged (MLL-r) leukemia is associated with poor prognosis.. Bromodomain and extra-terminal inhibitors (BETi) are promising agents for treatment of hematological malignancies; however, the mechanisms underlying sensitivity to BETi and biomarkers to predict sensitivity are yet to be clarified.. Here, we established OTX015-resistant MLL-r cell lines (OTX015R cells) and used them to explore therapeutic targets in BETi-resistant MLL-r leukemia. |
![HCT116 cells (5 × 10³ cells/well) were exposed for 48 h to increasing concentrations of (A) 5-fluorouracil (0.77–7700 μM), (B) SN-38 (0.02–200 nM), (C) oxaliplatin (0.125–250 μM), and (D) <t>the</t> <t>CDK4/6</t> inhibitors abemaciclib (25–3000 nM) or palbociclib (25–6400 nM). Cell viability was assessed by Calcein AM fluorescence and expressed as a percentage of the untreated control (100%). The data are presented as the mean ± SEM of six independent biological replicates. Dose–response curves were fitted by nonlinear regression using a four-parameter logistic model (variable slope; log[inhibitor] vs. normalized response) in GraphPad Prism 8.4.3.](https://bio-rxiv-images-cdn.bioz.com/dois_ending_with_43/10__64898_slash_2026__04__15__718743/10__64898_slash_2026__04__15__718743___F1.large.jpg)
